DEVELOPMENT AND CHARACTERIZATION OF HYDROXYL CHLOROQUINE SULPHATE (HCQ) NANOPARTICLES
Abstract
The objective of present study was to formulate and characterize the nanoparticles of hydroxyl chloroquine sulphate (HCQ). Nanoparticles were prepared by the w/o/w emulsion - solvent evaporation method using polymer Eudragit® RL-100, acetone, and surfactant poloxmer-188 solutions. Amount of polymer, organic solvent and surfactant was selected as formulation variable. Characterization of the nanoparticles was performed by measuring particle size, zeta potential, surface morphology, interactions, drug entrapment efficiency, in-vitro drug release, % yield and stability. The formulated nanoparticles were found to be spherical and uniform in particle size with less than one poly dispersity index. The zeta potential of nanoparticles was found -34 (mv) represent higher stability of colloidal dispersion. In another set of characterization the percentage yield and entrapment was found to be in the range of 55-68% and 63.14% respectively. The in-vitro release shows 87.93% at its maximum level in 24 hours of study. The suspension of formulation was found more stable in refrigerated environment. The release kinetics evaluation revealed the drug release was following Higuchi model, which ensures the possibility of long term release profile from the nanoparticles formulation so that its concentration maintained within therapeutic level for larger period of time so that safe and efficacious for malarial and rheumatoid patients.
Keywords:
Hydroxy chloroquine sulphate (HCQ), Nanoparticles, Rheumatoid arthritis, AntimalarialDOI
https://doi.org/10.25004/IJPSDR.2015.070104References
2. Galinski M, Barnwell JW. Plasmodium Vivax: Merozoite invasion of Reticulocytes and Considerations for Malaria Vaccine Development. Parasitol. Today 1996; 12:20-29.
3. Jordan P, Brookes JG, Nikolic G, Le Counteur D. Hydroxychloroquine overdose: toxicokinetics and management. J Toxicol Clin Toxicol. 1997; 37(7):861-864.
4. Kreuter. J. Nanoparticles, in Encyclopaedia of Pharmaceutical Technology, Swarbrick j, Marcel Dekker Inc. New York USA, 1994, pp. 165-90.
5. Barratt GM. Therapeutic Applications of Colloidal Drug Carriers. Pharm. Sci Technolo Today 2000; 3(5):163-171.
6. Pitt CG, Chasalow FI, Hibionada YM, Klimas DM, Schindler A. Aliphatic polyesters 1. The degradation of poly-caprolactone in vivo. J. Appl. Polym. Sci. 1983; 28:3779–87.
7. Fatal E, Youssef M, Couvreur P, Andremont A. Treatment of experimental salmonellosis in mice with amipicillin–bound nanoparticles. Antimicrobe Agents Chemother. 1989; 33(9): 1540-1543.
8. Kathleen D, Vandervoort J, Guy V, Annick L. Evaluation of Ciprofloxacin loaded Eudiragit® RS 100 or RL 100/PLGA Nanoparticles. International Journal of Pharmaceutics 2006; 314(1): 72-82.
9. PageClisson ME, PintoAlphandary H, Ourevitch M, Andremont A, Couvreur P. Development of ciprofloxacin-loaded nanoparticles: Physicochemical study of the drug carrier. J Contr Release 1998; 56:23–32.
10. Torchilin VP. Structure and design of polymeric surfactant based drug delivery systems. J Contr Release 2001; 73:137-172.
11. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 1989; 55: R1-R4.
12. ICH Q2A- Guidelines for Identify: Test on method validation of analytical procedure, March 1995.
13. ICH Q2B- Guidelines for industry validation of analytical procedure methodology, Nov. 1996.
Published
Abstract Display: 314 
PDF Downloads: 303 
